ES552539A0 - Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana - Google Patents

Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana

Info

Publication number
ES552539A0
ES552539A0 ES552539A ES552539A ES552539A0 ES 552539 A0 ES552539 A0 ES 552539A0 ES 552539 A ES552539 A ES 552539A ES 552539 A ES552539 A ES 552539A ES 552539 A0 ES552539 A0 ES 552539A0
Authority
ES
Spain
Prior art keywords
membrane
preparing
procedure
vaccine including
polypeptide fixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES552539A
Other languages
English (en)
Other versions
ES8705036A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27414978&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES552539(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES552539A0 publication Critical patent/ES552539A0/es
Publication of ES8705036A1 publication Critical patent/ES8705036A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ES552539A 1983-08-30 1986-02-28 Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana Expired ES8705036A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52791783A 1983-08-30 1983-08-30
US54755183A 1983-10-31 1983-10-31
US58817084A 1984-03-09 1984-03-09

Publications (2)

Publication Number Publication Date
ES552539A0 true ES552539A0 (es) 1987-05-01
ES8705036A1 ES8705036A1 (es) 1987-05-01

Family

ID=27414978

Family Applications (2)

Application Number Title Priority Date Filing Date
ES535554A Expired ES8605039A1 (es) 1983-08-30 1984-08-30 Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.
ES552539A Expired ES8705036A1 (es) 1983-08-30 1986-02-28 Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES535554A Expired ES8605039A1 (es) 1983-08-30 1984-08-30 Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.

Country Status (13)

Country Link
US (1) US5851533A (es)
EP (1) EP0139417B2 (es)
JP (2) JP2599350B2 (es)
AU (1) AU579323B2 (es)
CA (1) CA1341181C (es)
DE (1) DE3479085D1 (es)
DK (2) DK172694B1 (es)
ES (2) ES8605039A1 (es)
GR (1) GR80220B (es)
HK (1) HK98792A (es)
IE (1) IE58030B1 (es)
IL (1) IL72785A (es)
NZ (1) NZ209308A (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
NZ209307A (en) * 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
GR862472B (en) * 1986-09-30 1986-10-09 Elliniko Institouto Paster Determination of antibodies specific of hsv-1 herpes or hsv-2 in human serum with the elisa technic using the specific antigen of hsv-1 or hsv-2 type in semi - clean form
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
WO1990013652A1 (en) * 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
EP0483281A4 (en) * 1989-07-31 1992-08-12 Basil Rapaport Recombinant human thyroid peroxidase
WO1993005072A1 (en) * 1991-08-28 1993-03-18 Basil Rapoport Disease associated human autoantibodies specific for human thyroid peroxidase
EP0541692B1 (en) * 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
WO2002016420A2 (en) * 2000-08-01 2002-02-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiviral compounds derived from the hsv gd protein and methods
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
BRPI0518284A2 (pt) 2004-11-24 2008-11-11 Shell Int Research aparelhos para separar substancialmente um fluxo em duas fases em um componente gasoso e um componente lÍquido, para separar substancialmente um fluxo de mistura em um componente lÍquido e pelo menos outro componente lÍquido e um componente gasoso e para separar substancialmente um fluxo de mistura em partes componentes com base nas densidades das partes componentes, sistema para separar substancialmente um fluxo de mistura em partes componentes, e, mÉtodos para separar substancialmente um fluxo tampço e para projetar um separador para separar substancialmente um fluxo tampço
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US8871223B2 (en) 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
CN101616688B (zh) * 2006-12-28 2013-12-11 宾夕法尼亚大学理事会 单纯疱疹病毒联合亚单位疫苗及其使用方法
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
MX2012005598A (es) 2009-12-03 2012-05-29 Novartis Ag Filtracion hidrofilica durante la fabricacion de adyuvantes de vacuna.
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
ES2573710T3 (es) 2009-12-03 2016-06-09 Novartis Ag Circulación de componentes durante la homogeneización y de microfluidización de emulsiones
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PT2380558E (pt) 2009-12-03 2012-11-27 Novartis Ag Disposição de câmaras de interacção e de contrapressão para microfluidização
PT3489211T (pt) 2010-05-12 2020-09-22 Novartis Ag Métodos aperfeiçoados para preparar esqualeno
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2850431B1 (en) 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US20230218526A1 (en) 2020-06-30 2023-07-13 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
US4374127A (en) * 1977-09-19 1983-02-15 Merck & Co., Inc. Herpes sub unit vaccine
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
US4317811A (en) * 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
EP0068693A3 (en) 1981-06-16 1983-07-20 Genentech, Inc. Production of foot and mouth disease vaccine from microbially expressed antigens
ZW18282A1 (en) 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US4891315A (en) * 1982-10-25 1990-01-02 American Cyanamid Company Production of herpes simplex viral porteins
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
DK305784A (da) * 1983-06-23 1984-12-24 Stanley Person Ikke-glycosyleret aminosyrekaede af glycoprotein b fra herpes virus type 1 og 2
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
EP0628633B1 (en) * 1984-04-06 2003-01-08 Chiron Corporation Recombinant herpes simplex gB-gD vaccine
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
EP0170169B1 (en) * 1984-07-20 1991-03-20 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant dna containing a herpes simplex virus gene or a fragment thereof, yeast transformed with said recombinant dna, and method for the production of herpes simplex virus proteins

Also Published As

Publication number Publication date
JP2599350B2 (ja) 1997-04-09
DK9197A (da) 1997-01-24
JPH08253428A (ja) 1996-10-01
IL72785A (en) 1990-07-26
JPS60155128A (ja) 1985-08-15
NZ209308A (en) 1991-08-27
DK412284A (da) 1985-04-11
ES8605039A1 (es) 1986-03-16
HK98792A (en) 1992-12-18
DK412284D0 (da) 1984-08-29
EP0139417B1 (en) 1989-07-26
ES535554A0 (es) 1986-03-16
AU579323B2 (en) 1988-11-24
IE58030B1 (en) 1993-06-16
CA1341181C (en) 2001-02-20
DK172694B1 (da) 1999-05-31
US5851533A (en) 1998-12-22
EP0139417B2 (en) 1999-03-17
IE842210L (en) 1985-02-28
EP0139417A1 (en) 1985-05-02
ES8705036A1 (es) 1987-05-01
DE3479085D1 (en) 1989-08-31
AU3242384A (en) 1985-03-07
IL72785A0 (en) 1984-11-30
GR80220B (en) 1984-11-15

Similar Documents

Publication Publication Date Title
ES552539A0 (es) Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana
ES526524A0 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
ES557048A0 (es) Procedimiento para preparar peptidos triofluormetilcetona-sustituidos
MX159153A (es) Membrana compuesta semipermeable y procedimiento para su fabricacion
ES544257A0 (es) Procedimiento para preparar nuevos acidos 3-(5-aminopentil)-amino-1-benzazepin-2-ona-1-alcanoico
ES537520A0 (es) Un procedimiento para preparar nuevos peptidos atriales.
NO842962L (no) Fremgangsmaate for fremstilling av et polypeptid egnet for anvendelse i en vaksinasjonsprosedyre
ES489884A0 (es) Un metodo mejorado para preparar una membrana anisotropa
ES545607A0 (es) Procedimiento para preparar una vacuna contra la coccidiosis
AR230634A1 (es) Procedimiento para preparar una solucion para inyeccion
ES534694A0 (es) Un procedimiento para preparar cefuroxima sodica
IT8467874A0 (it) Procedimento per la incapsulazione di un anima in una membrana semipermeabile e capsula provvista di membrana semipermeabile
MX161186A (es) Procedimiento para preparar peptidos
ES529298A0 (es) Un procedimiento para la preparacion de una vacuna contra picornavirus
ES526072A0 (es) Un procedimiento para preparar amidas sustituidas con alcohol
ES545606A0 (es) Procedimiento para preparar una vacuna contra la coccidiosis
ES547004A0 (es) Un procedimiento para preparar hidantoinas opticamente acti-vas
MX7528E (es) Procedimiento para la preparacion de una vacuna sintetica
ES535455A0 (es) Un procedimiento para preparar peptidos
ES497154A0 (es) Procedimiento para preparar una fibra hueca semipermeable decelulosa
ES554582A0 (es) Procedimiento para preparar una composicion de zirconio
ES534170A0 (es) Un procedimiento para preparar 1-piridil-alquil-4-aril-piperazinas
ES532788A0 (es) Procedimiento para la fabricacion de una membrana de estanquidad
ES533114A0 (es) Un procedimiento para la preparacion de una membrana semipermeable polipropilenica
AR240819A1 (es) Procedimiento para preparar una benzoquinolicina

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070307